Historical Valuation
Tarsus Pharmaceuticals Inc (TARS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 5.30 is considered Undervalued compared with the five-year average of 112.45. The fair price of Tarsus Pharmaceuticals Inc (TARS) is between 2576.14 to 2886.39 according to relative valuation methord. Compared to the current price of 76.87 USD , Tarsus Pharmaceuticals Inc is Undervalued By 97.02%.
Relative Value
Fair Zone
2576.14-2886.39
Current Price：76.87
97.02%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Tarsus Pharmaceuticals Inc (TARS) has a current Price-to-Book (P/B) ratio of 10.23. Compared to its 3-year average P/B ratio of 5.15 , the current P/B ratio is approximately 98.52% higher. Relative to its 5-year average P/B ratio of 4.17, the current P/B ratio is about 145.59% higher. Tarsus Pharmaceuticals Inc (TARS) has a Forward Free Cash Flow (FCF) yield of approximately -1.68%. Compared to its 3-year average FCF yield of -9.47%, the current FCF yield is approximately -82.27% lower. Relative to its 5-year average FCF yield of -6.97% , the current FCF yield is about -75.92% lower.
P/B
Median3y
5.15
Median5y
4.17
FCF Yield
Median3y
-9.47
Median5y
-6.97
Competitors Valuation Multiple
AI Analysis for TARS
The average P/S ratio for TARS competitors is 755.84, providing a benchmark for relative valuation. Tarsus Pharmaceuticals Inc Corp (TARS.O) exhibits a P/S ratio of 5.30, which is -99.3% above the industry average. Given its robust revenue growth of 146.68%, this premium appears sustainable.
Performance Decomposition
AI Analysis for TARS
1Y
3Y
5Y
Market capitalization of TARS increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of TARS in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is TARS currently overvalued or undervalued?
Tarsus Pharmaceuticals Inc (TARS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 5.30 is considered Undervalued compared with the five-year average of 112.45. The fair price of Tarsus Pharmaceuticals Inc (TARS) is between 2576.14 to 2886.39 according to relative valuation methord. Compared to the current price of 76.87 USD , Tarsus Pharmaceuticals Inc is Undervalued By 97.02% .
What is Tarsus Pharmaceuticals Inc (TARS) fair value?
TARS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Tarsus Pharmaceuticals Inc (TARS) is between 2576.14 to 2886.39 according to relative valuation methord.
How does TARS's valuation metrics compare to the industry average?
The average P/S ratio for TARS's competitors is 755.84, providing a benchmark for relative valuation. Tarsus Pharmaceuticals Inc Corp (TARS) exhibits a P/S ratio of 5.30, which is -99.30% above the industry average. Given its robust revenue growth of 146.68%, this premium appears sustainable.
What is the current P/B ratio for Tarsus Pharmaceuticals Inc (TARS) as of Jan 11 2026?
As of Jan 11 2026, Tarsus Pharmaceuticals Inc (TARS) has a P/B ratio of 10.23. This indicates that the market values TARS at 10.23 times its book value.
What is the current FCF Yield for Tarsus Pharmaceuticals Inc (TARS) as of Jan 11 2026?
As of Jan 11 2026, Tarsus Pharmaceuticals Inc (TARS) has a FCF Yield of -1.68%. This means that for every dollar of Tarsus Pharmaceuticals Inc’s market capitalization, the company generates -1.68 cents in free cash flow.
What is the current Forward P/E ratio for Tarsus Pharmaceuticals Inc (TARS) as of Jan 11 2026?
As of Jan 11 2026, Tarsus Pharmaceuticals Inc (TARS) has a Forward P/E ratio of 96.15. This means the market is willing to pay $96.15 for every dollar of Tarsus Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Tarsus Pharmaceuticals Inc (TARS) as of Jan 11 2026?
As of Jan 11 2026, Tarsus Pharmaceuticals Inc (TARS) has a Forward P/S ratio of 5.30. This means the market is valuing TARS at $5.30 for every dollar of expected revenue over the next 12 months.